delafloxacin meglumine
Trade name: baxdela
Small moleculeapprovedFast Track FDA
Approved
Jun 19, 2017
Delafloxacin sold under the brand name Baxdela among others, is a fluoroquinolone antibiotic used to treat acute bacterial skin and skin structure infections. It was developed by Melinta Therapeutics. — Wikipedia
Clinical trial activity
0 trials · 0 clinical orgs · 1 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0
Timeline
2010s
- Jun 19, 2017
Melinta Therapeutics — Earliest FDA Approval
- Jun 19, 2017
Melinta Therapeutics — NDA Secondary Org
- Jun 19, 2017
Melinta Therapeutics — NDA Organization
Indications
Approved for
Mechanism of action
- Topoisomerase IVINHIBITOR
Topoisomerase IV inhibitor
- Bacterial DNA gyraseINHIBITOR
Bacterial DNA gyrase inhibitor
Approval history
- approvedPriority reviewFast trackJun 19, 2017
Chemistry & pharmacology
Loading structure…
SMILES
CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.Nc1nc(-n2cc(C(=O)O)c(=O)c3cc(F)c(N4CC(O)C4)c(Cl)c32)c(F)cc1F- Mol. weight
- 635.98 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral, Parenteral
- Availability
- Prescription Only
Oral
Yes
Parenteral
Yes
Topical
No
Black box warning
Sources
- ChEMBLCHEMBL2105638 ↗
- WikipediaDelafloxacin ↗
Also known as
- delafloxacin meglumine
Organizations
Marketing (2)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Melinta Therapeutics | For profit | NDA2 | Jun 19, 2017 |
| Melinta Therapeutics | For profit | NDA | Jun 19, 2017 |